Loading stock data…
Armata Pharmaceuticals, Inc. (ARMP)
$6.36-1.04 (-14.05%)
Market OpenUpdated 12:39 PM EDT
Armata Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Armata Pharmaceuticals, Inc. in the Healthcare sector is trading at $6.36 with a market capitalization of $286M. Wall Street consensus targets $17.50 (2 analysts), implying a +175.2% move over the next 12 months. The stock is currently 61% below its 52-week high of $16.34, remaining 13.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +175.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.79M↓ | -$8.41M↓ | -$7.78M↓ | -$6.84M↑ | -$8.19M |
| Net Income | -$115.35M↑ | -$124.30M↓ | -$26.68M↓ | -$16.30M↓ | -$6.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$286.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
90.70%
Volume
Today's trading volume
126,588
Recent News
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?
Armata Pharmaceuticals Inc. (NYSE:ARMP) is one of the high-growth micro-cap stocks to buy now. On May 7, Armata Pharmaceuticals Inc. (NYSE:ARMP) achieved a significant milestone when the U.S Food and Drug Administration granted Fast Track Designation to AP-SA02. AP-SA02 is the company’s intravenously administered multi-phage product for the treatment of complicated bacteremia caused by Staphylococcus […]
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after […]
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?